A Retrospective Study of the Efficacy and Safety of Levofloxacin in Children with Severe Infection

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2024 Apr 22

PMID 38646513

Authors

Zhang Junqi

Cai Jie

Wang Jinglin

Lu Jinmiao

Lu Guoping

Wang Yi

Li Zhiping

Affiliations

Soon will be listed here.

Abstract

Objectives: Levofloxacin is widely used because of its broad-spectrum antimicrobial activity and convenient dosing schedule. However, the relevance of its use in children remains to be investigated. The purpose of this study is to investigate the efficacy and safety of levofloxacin use in children with severe infections.

Methods: We conducted a retrospective observational study of patients <18 years of age who received levofloxacin intravenously in the Pediatric Intensive Care Unit (PICU) of our hospital during the period between 2021 and 2022. Patient demographics, course characteristics, clinical effectiveness, and adverse event correlations were extracted through a retrospective tabular review.

Results: We included 25 patients treated with 28 courses of levofloxacin. The mean age of these children treated with levofloxacin was 4.41 years. Conversion of pathogenic microbiological test results to negative after levofloxacin treatment was detected in 11 courses (39.29%). A decrease in inflammatory markers, white blood cell or C-reactive protein counts, was detected in 18 courses (64.29%). A total of 57 adverse events occurred during the treatment period, of which 21 were possibly related to levofloxacin and no adverse events were probably related to levofloxacin.

Conclusion: The effectiveness of levofloxacin use in children with serious infections is promising, especially for the treatment of multidrug-resistant bacteria. Adverse events occurring during the initiation of levofloxacin therapy in children are reported to be relatively common, but in this study, only a small percentage of them were possibly related to levofloxacin, and none of them were highly possibly related to levofloxacin.

References

Kranz J, Schmidt S, Lebert C, Schneidewind L, Vahlensieck W, Sester U . [Epidemiology, diagnostics, therapy, prevention and management of uncomplicated bacterial outpatient acquired urinary tract infections in adult patients : Update 2017 of the interdisciplinary AWMF S3 guideline]. Urologe A. 2017; 56(6):746-758. DOI: 10.1007/s00120-017-0389-1. View

Grady R . Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J. 2003; 22(12):1128-32. DOI: 10.1097/01.inf.0000101994.25947.12. View

Agbabiaka T, Savovic J, Ernst E . Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2007; 31(1):21-37. DOI: 10.2165/00002018-200831010-00003. View

Arimone Y, Begaud B, Miremont-Salame G, Fourrier-Reglat A, Molimard M, Moore N . A new method for assessing drug causation provided agreement with experts' judgment. J Clin Epidemiol. 2006; 59(3):308-14. DOI: 10.1016/j.jclinepi.2005.08.012. View

Karol S, Sun Y, Tang L, Pui C, Ferrolino J, Allison K . Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia. Cancer Med. 2020; 9(18):6550-6555. PMC: 7520302. DOI: 10.1002/cam4.3249. View

Bradley J, Byington C, Shah S, Alverson B, Carter E, Harrison C . The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011; 53(7):e25-76. PMC: 7107838. DOI: 10.1093/cid/cir531. View

Tamma P, Aitken S, Bonomo R, Mathers A, van Duin D, Clancy C . Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis. 2023; . DOI: 10.1093/cid/ciad428. View

Guarino A, Ashkenazi S, Gendrel D, Lo Vecchio A, Shamir R, Szajewska H . European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr. 2014; 59(1):132-52. DOI: 10.1097/MPG.0000000000000375. View

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

10.

Bush L, Kaye D . Catheter-associated urinary tract infection IDSA guidelines: why the levofloxacin?. Clin Infect Dis. 2010; 51(4):479-80. DOI: 10.1086/655159. View

11.

Zagari R, Frazzoni L, Marasco G, Fuccio L, Bazzoli F . Treatment of Helicobacter pylori infection: a clinical practice update. Minerva Med. 2020; 112(2):281-287. DOI: 10.23736/S0026-4806.20.06810-X. View

12.

. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399(10325):629-655. PMC: 8841637. DOI: 10.1016/S0140-6736(21)02724-0. View

13.

Chow A, Benninger M, Brook I, Brozek J, Goldstein E, Hicks L . IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012; 54(8):e72-e112. DOI: 10.1093/cid/cir1043. View

14.

Bacci C, Galli L, de Martino M, Chiappini E . Fluoroquinolones in children: update of the literature. J Chemother. 2015; 27(5):257-65. DOI: 10.1179/1973947815Y.0000000054. View

15.

Jantarabenjakul W, Suntarattiwong P, Wacharachaisurapol N, Supradish Na Ayudhya P, Phaisal W, Tawan M . Pharmacokinetics and Safety of WHO-Recommended Dosage and Higher Dosage of Levofloxacin for Tuberculosis Treatment in Children: a Pilot Study. Int J Infect Dis. 2022; 122:603-608. DOI: 10.1016/j.ijid.2022.07.029. View

16.

Lehrnbecher T, Fisher B, Phillips B, Alexander S, Ammann R, Beauchemin M . Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation. Clin Infect Dis. 2019; 71(1):226-236. PMC: 7312235. DOI: 10.1093/cid/ciz1082. View

17.

Laxminarayan R . The overlooked pandemic of antimicrobial resistance. Lancet. 2022; 399(10325):606-607. PMC: 8769677. DOI: 10.1016/S0140-6736(22)00087-3. View

18.

Bradley J, Kauffman R, Balis D, Duffy C, Gerbino P, Maldonado S . Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics. 2014; 134(1):e146-53. DOI: 10.1542/peds.2013-3636. View

19.

Emmi V . [Guidelines for treatment of pneumonia in intensive care units]. Infez Med. 2006; Suppl:7-17. View

20.

Hampel B, Hullmann R, Schmidt H . Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use--safety report. Pediatr Infect Dis J. 1997; 16(1):127-9; discussion 160-2. DOI: 10.1097/00006454-199701000-00036. View